Vincerx Pharma Company Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.

Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer.

The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.

Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Vincerx Pharma, Inc.

Country	United States
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	13
CEO	Raquel Izumi

Contact Details

Address: 1825 S. Grant Street San Mateo, California California United States
Phone	650 800 6676

Stock Details

Ticker Symbol	VINC
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US92731L1061
SIC Code	2836

Key Executives

Name	Position
Dr. Raquel E. Izumi Ph.D.	Co-Founder, Acting Chief Executive Officer, Secretary and Director
Tom C. Thomas J.D.	Consultant
Alexander A. Seelenberger M.B.A.	Consultant
Dr. John C. Byrd M.D.	Founder and Chairman of Scientific Advisory Board
Kevin Haas	Acting Chief Financial Officer, Vice President of Finance and Corporate Controller
Dr. Hans-Georg Lerchen Ph.D.	Chief Scientific Officer
Gabriela Jairala	Vice President of Investor Relations and Corporate Communications and Chief of Staff
Karen Quarford M.B.A.	Vice President of Quality Operations and Compliance
Melissa Merrick SPHR	Senior Director of People and Culture and Head of Human Resource
Dr. Beatrix Stelte-Ludwig Ph.D.	Executive Chief Development Officer